Key Highlights

  • NRC Health's $0.16 quarterly Dividend trades ex-date September 25, 2026, payable October 9, unchanged from the prior quarter.
  • Second-quarter Revenue was $35.4 million, up 4% year over year, with a GAAP net loss of $3.3 million but adjusted Net Income of $6.9 million.
  • Total Recurring Contract Value (TRCV) rose 11% year over year to $151.9 million, the strongest growth in several quarters.
  • Adjusted EBITDA was $9.4 million, representing 27% of revenue, while free Cash Flow was $0.1 million after approximately $2.9 million of cash payments tied to executive-transition costs.

Overview

NRC Health's (NASDAQ:NRC) $0.16 quarterly dividend yields approximately 2.97% and continued unchanged through a quarter in which GAAP results reflected a net loss driven substantially by previously disclosed executive-transition and equity-compensation costs, while the company's forward-looking TRCV metric grew at its strongest pace in several quarters. The dividend is evaluated against both GAAP and adjusted results, given the specifically identified, non-recurring nature of the items affecting this quarter's reported loss.

Dividend Program and Shareholder Returns

NRC Health's board declared a quarterly Cash Dividend of $0.16 per share on July 15, 2026, payable October 9 to shareholders of record September 25. The dividend is a regular quarterly common-stock distribution, equal to $0.64 annualized if maintained, and remains subject to Board approval each quarter.

About the Company

NRC Health provides technology, research, advisory and engagement solutions to healthcare organizations, focused on understanding patients, consumers and communities to help providers improve experience and outcomes. The company has operated in healthcare experience improvement for more than 45 years.

Financial Performance Behind the Payout

NRC Health reported second-quarter total revenue of $35.4 million, up 4% from $34.038 million a year earlier. GAAP net loss was $3.3 million, or $0.15 loss per fully diluted share, while adjusted net income was $6.9 million, or $0.31 adjusted diluted EPS, with the adjustment primarily reflecting accelerated vesting of stock and associated cash bonuses tied to executive transition. Adjusted EBITDA was $9.4 million, representing 27% of revenue. TRCV, an operating metric distinct from GAAP revenue, was $151.9 million, up 11% year over year. Net cash flow from Operating Activities was $1.4 million, and free cash flow was $0.1 million, both reflecting approximately $2.9 million of cash payments related to the adjustment items.

A GAAP Loss Explained by Specifically Identified, Non-Recurring Items

The gap between GAAP net loss of $3.3 million and adjusted net income of $6.9 million is attributable to previously announced accelerated stock vesting and associated cash bonuses tied to executive transition, a specifically identified item management separates from underlying operating performance; approximately $2.9 million of cash payments tied to those items also depressed free cash flow to $0.1 million for the quarter. TRCV growth of 11% to $151.9 million, described as the strongest pace in several quarters, is a leading indicator of future revenue distinct from the 4% growth in recognized GAAP revenue during the same period. Management has said it expects third-quarter revenue to increase sequentially and adjusted EBITDA Margin to remain approximately in line with the first half, with margin expansion anticipated in the second half as Recurring Revenue increasingly reflects the higher TRCV generated over recent quarters.

Outlook

NRC Health's dividend has remained $0.16 per share. TRCV growth trends relative to the 11% pace reported this quarter, the cash-flow effect of executive-transition costs as those payments conclude, and anticipated second-half margin expansion are the relevant considerations.